Full-Body MRI Screening Cost (2026)

Full-body MRI screening in the United States costs $999 to $4,500 per scan in 2026, with most major consumer providers priced as follows: Ezra base scan $1,495, Ezra enhanced $2,495, Prenuvo $2,499, Q Bio $3,495, and Princeton Longevity Center comprehensive packages $3,995-$4,995. Pricing is similar across geographic markets as most providers use centralized national pricing. Most insurance plans do not cover full-body MRI as preventive screening; HSA and FSA accounts may be applicable.

This is one of the most-debated questions in current preventive medicine. The evidence base is limited: no randomized controlled trial has demonstrated that full-body MRI screening in asymptomatic adults reduces all-cause mortality or cancer-specific mortality. Observational data shows clinically significant cancers are detected in approximately 1-2 percent of asymptomatic adults screened, but incidental findings (mostly benign) occur in 30-50 percent of patients, generating downstream costs and risks. Major US medical societies do not recommend it as routine screening but acknowledge potential value for high-risk individuals (cancer survivors, BRCA carriers, strong family history).

Full-body MRI scans typically take 45 to 90 minutes depending on provider and protocol. Prenuvo scans average 60 minutes, Ezra base scans 30-45 minutes, Q Bio scans 60-90 minutes. Most patients lie still in the scanner during this time with brief pauses between sequences.

Most US insurance plans do not cover full-body MRI for preventive screening in asymptomatic adults, as major medical societies do not currently recommend it as a routine screening modality. HSA (Health Savings Account) and FSA (Flexible Spending Account) funds may be used to pay (consult your tax advisor). Some employers offer full-body MRI as an executive benefit. If a physician orders a targeted MRI for a specific symptom or risk factor, insurance coverage is more likely.

Full-body MRI can detect tumors larger than approximately 5-10 mm in many organ systems including liver, kidney, brain, ovaries, pancreas, and lymph nodes. It may detect aneurysms, cysts, fatty liver disease, vertebral abnormalities, and joint conditions. It does not reliably detect very small early-stage cancers in many locations, lung cancers (CT is preferred), prostate cancers (dedicated prostate MRI is preferred), gastrointestinal mucosal cancers (endoscopy is preferred), or hematologic cancers (blood tests required).

All three providers offer consumer full-body MRI screening with similar core service. Prenuvo has the most locations and aggressive consumer marketing, priced at $2,499. Ezra offers tiered pricing ($1,495 base, $2,495 enhanced) and emphasizes AI-augmented analysis. Q Bio offers more extensive imaging plus blood-test integration at higher pricing ($3,495). Scan protocols and image quality are broadly similar, with all using 3-Tesla MRI and board-certified radiologist interpretation.

There is no evidence-based recommendation for routine repeat frequency. Some providers suggest annual rescanning to detect change; others recommend every 2-3 years; some recommend a single baseline scan with targeted follow-up only if findings are detected. Annual scanning has the highest potential to detect new findings but also generates highest cumulative costs and incidental finding workup.

No. Full-body MRI does not replace mammography (dedicated breast imaging), colonoscopy (direct visualization of colon mucosa), low-dose CT lung screening (radiation-based imaging optimized for early lung cancer), or other evidence-based screenings. A negative full-body MRI should not be used as justification to skip recommended traditional screening tests.

Most providers triage findings into actionable (requiring further workup), watchful waiting (recommended repeat imaging), or incidental (no action needed). The provider typically recommends next steps and forwards results to your personal physician. Cost of follow-up workup ranges from a few hundred dollars (repeat imaging) to thousands of dollars (biopsy, specialist visits, additional scans). Most incidental findings are benign.

MRI itself involves no ionizing radiation and is considered safe for repeat use. Most consumer full-body MRI protocols are non-contrast, avoiding gadolinium-related concerns. The main risks are not from the scan itself but from the cascade of follow-up workup for incidental findings (procedural risks of biopsy, additional imaging exposures, psychological stress of indeterminate findings).

Roughly 5-10 percent of patients have difficulty completing MRI scans due to claustrophobia. Mitigation strategies include sedation (oral anti-anxiety medications), open MRI machines (with lower image quality), positional adjustments (feet-first vs head-first), and abbreviated protocols. Discuss with the provider in advance.

The American College of Radiology, American Cancer Society, US Preventive Services Task Force, and other major bodies do not currently recommend whole-body MRI as routine screening in asymptomatic adults. Reasons include: absence of randomized trial evidence of mortality benefit, high rate of incidental findings generating downstream costs and risks, lack of standardized protocols across providers, and concerns about overdiagnosis. These bodies acknowledge potential value for high-risk individuals but do not currently support population-wide use.